mbiomics, a Bavaria-based BioTech startup advancing scalable microbiome-based therapeutics for severe and chronic diseases, has announced the third closing of its Series A round at €12 million, bringing the total round size to €30 million. The round includes participation from existing investors, including MIG Fonds and Bayern Kapital. According to
Rahul Raj
